Diagnostic accuracy is a foundational pillar of effective oncological care, yet persistent challenges in imaging and pathology continue to pose risks to patient safety. Research indicates that approximately 795,000 Americans experience permanent disability or death each year as a result of diagnostic errors, contributing to an estimated economic burden exceeding $100 billion (Newman-Toker et al., BMJ Quality & Safety, 2023).
Within clinical oncology, cancers collectively are classified among the “Big Three” conditions — alongside vascular events and infections — that are most susceptible to severe diagnostic harm. While advances in radiological interpretation continue to improve the detection of early-stage malignancies, the complexity of modern oncology calls for a more rigorous, evidence-based approach to minimising errors across the diagnostic pathway.
Clinical Drivers of Imaging Errors in Oncology
Diagnostic errors in oncology often arise from a combination of interpretive challenges and cognitive biases. A useful clinical distinction is drawn between radiology, which concerns the interpretation of gross anatomical structures through imaging, and pathology, which involves the microscopic analysis of tissue. Each discipline carries its own specific failure points within the diagnostic chain.
Modality-Specific Challenges
Melanoma. Initial assessment is largely visual, and the decision to biopsy depends on clinical suspicion based on dermoscopic features. Misinterpretation at this stage may delay histopathological confirmation, which remains the diagnostic gold standard.
Breast cancer. High breast density is a recognised driver of false-negative mammography results, as dense fibroglandular tissue can obscure underlying malignant clusters. In addition, the interpretation of breast biopsies is subject to a degree of inter-observer variability, which highlights the need for standardised review processes.
Lung cancer. On CT imaging, early-stage malignant nodules may be morphologically similar to benign granulomas or post-inflammatory scarring. Reducing diagnostic uncertainty in these cases typically requires adherence to longitudinal tracking protocols or PET-CT correlation.
Demographic Disparities in Diagnostics
Evidence indicates that diagnostic errors do not affect all patient populations equally. Studies have reported that women and certain racial minorities face a 20 to 30 per cent higher risk of misdiagnosis compared with other groups (Newman-Toker et al., 2019).
Minority populations often experience higher rates of late-stage cancer diagnoses, a pattern attributed in part to systemic barriers to care and, in some cases, to algorithmic biases embedded in diagnostic software. Women are more likely to have their symptoms attributed to non-serious causes, particularly in cases of lung and colorectal cancers. Addressing these gaps requires both standardised review protocols and a sustained effort to broaden demographic representation in clinical trials, so that diagnostic tools and reference standards reflect the populations they are intended to serve.
The Role of Artificial Intelligence in Oncology Imaging
Artificial intelligence is increasingly being explored as a tool to assist radiologists in processing high-volume imaging datasets. In experimental settings, these systems have demonstrated promising sensitivity in identifying features such as squamous cell carcinoma signatures. It is important, however, to distinguish between these experimental findings and established clinical practice.
At present, the integration of AI into oncology workflows is largely confined to decision support, rather than autonomous diagnosis. Several considerations shape its current clinical role.
AI models often excel at flagging microscopic anomalies, reflecting high sensitivity, but this can be accompanied by elevated false-positive rates that may lead to unnecessary biopsies and patient anxiety. The performance of these systems is also closely tied to the diversity of their training data; limited demographic breadth can introduce bias, particularly in breast and skin imaging applications. In more complex scenarios, some multimodal AI tools applied to CT imaging have shown error rates approaching 20 per cent when faced with rare pathological variants or atypical presentations that fall outside the training distribution.
These limitations do not diminish the potential of AI in oncology, but they reinforce the importance of careful validation, transparent reporting of performance, and continued human oversight as these tools mature.
Enhancing Quality through Multidisciplinary Review
To mitigate the effects of human fatigue and the inherent limitations of algorithmic tools, imaging services are increasingly adopting secondary review and multidisciplinary frameworks.
A secondary review by a sub-specialised radiologist has been shown to alter the primary diagnosis in 10 to 20 per cent of complex oncological cases. This is particularly important for identifying subtle staging errors, which can directly influence the selection of chemotherapy or radiation protocols.
The table below summarises the principal review frameworks currently in use.
Standardising the Path Forward
Improving diagnostic outcomes in oncology requires a coordinated approach focused on clinical consistency and rigorous oversight.
Structured reporting systems, such as BI-RADS for breast imaging and LI-RADS for liver imaging, play an important role in reducing lexical ambiguity in communication between radiologists and oncologists, ensuring that findings are interpreted consistently across institutions. Alongside these reporting standards, strict human oversight remains essential. To guard against automation bias, AI outputs should be validated by board-certified radiologists before final diagnostic reports are issued.
Systemic accountability is further reinforced through internal quality assurance audits and adherence to established standards of care. Routine review of diagnostic discrepancies, whether through institutional QA processes or peer-review programmes, provides a valuable feedback mechanism that helps healthcare institutions refine their secondary review protocols and reporting standards over time. Diagnostic errors in cancers, vascular events, and infections also represent the leading categories of serious harm in malpractice claims (Newman-Toker et al., Diagnosis, 2019), and in cases where patients believe a serious diagnostic error has caused them harm, specialised medical misdiagnosis attorneys can help them understand their legal options and navigate the standard-of-care questions that often arise in such situations.
By focusing on these radiological and pathological best practices, imaging services can reduce the incidence of preventable harm and help ensure that oncology patients receive timely, evidence-based care.
Disclaimer: The information presented in this article is intended for educational and informational purposes only and should not be interpreted as medical, legal, or professional advice. While every effort has been made to ensure accuracy, developments in oncology imaging, artificial intelligence, and diagnostic standards may change over time. Readers should consult qualified healthcare professionals regarding specific medical concerns or diagnostic decisions. References to legal matters or medical misdiagnosis claims are provided for general awareness and do not constitute legal guidance or endorsement of any services
home » blog » health matters »
